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Abstract
Smoking cessation is essential for COPD patients. It mitigates the progression of the disease 
and the loss of ventilatory capacity, thus improving the overall prognosis. Overall mortality 
can be reduced effectively including mortality from respiratory diseases as well as lung can-
cer and cardiovascular diseases. Its main goal must be to initiate tobacco cessation as early 
as possible after diagnosing COPD so as to enable the patient to influence the course of this 
disease in the most effective way possible. Depending on the degree of tobacco addiction, 
the application of behavioural therapy combined with pharmaceutical support has shown 
to be the most reliable therapy with highest long-term abstinence rates. Particular consid-
eration is needed for patients with psychiatric comorbidity mainly represented by depres-
sion. The setting of tobacco cessation measures in outpatient clinics or practices embedded 
in long-term therapy of the underlying respiratory disease appears to be crucial for long-
time abstinence.
Keywords: smoking cessation, behavioural therapy, nicotine replacement, varenicline, 
bupropione, abstinence rates, e-cigarette
1. Introduction
In continuous long-term smokers, the exposition of the bronchial mucosa to the toxic compo-
nents of cigarette smoke results in a progressive inflammatory process with the  consequence 
of functional and structural destruction of the airways. Thus, the ventilatory capacity in 
terms of respiratory volumes FEV1 and VC is reduced and hyperinflation/development of 
emphysema is increased in accelerated speed and patients face respiratory failure with step-
wise progression of the disease [1–3]. After progression of lung function loss, gas exchange 
for oxygen and carbon dioxide is compromised resulting in hypoxaemia and  hypercapnia. 
The patient’s exercise ability is reduced to a minimum bringing him into the position that 
he needs help in even basic daily activities. Pharmaceutical therapy to relieve—mostly 
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inhalation therapy—will not be a sufficient intervention and long-term oxygen therapy, 
nocturnal ventilation therapy, volume reduction measures up to lung transplantation may 
be considered. In addition as a consequence of the mucosa destruction, the bronchial sys-
tem progressively loses the ability of mucociliary clearance resulting in higher deposition 
rates of the toxic components of smoke, thus enabling these substances to act carcinogenic. 
Consequently, continuous smokers with COPD show higher lung cancer rates compared to 
non-COPD individuals [4–6]. Smoking cessation, thus, must be the first measure to be taken 
in the treatment of COPD patients at the earliest possible time. Yet, in spite of this knowledge, 
a great proportion continues smoking due to various barriers among which the high degree 
of addiction is to be mentioned in the first place. Moreover, physicians sometimes consider 
smoking cessation therapy as addiction therapy as not their business or state that the major-
ity of and former smokers had stopped on their own and by pure willpower [7], or out of sec-
tion non-predictable “catastrophic” decision [8], thus neglecting the urgent need to stop the 
toxic smoke exposition of the bronchi as early as possible. The earlier tobacco consumption is 
stopped, the less the disease will develop and compromise the patient‘s prognosis.
2. Evidence and rationale of smoking cessation in COPD patients
Smoking is the main cause of COPD. Close to 90% of patients with COPD have a continuous 
smoking history. One of three continuous smokers develops COPD disease [9–12].
Susceptibility to smoke differs in gender and races. Women have a higher susceptibility to 
smoke compared to men, the same applies to African-American people compared to Caucasians 
[13–16].
Smoking and COPD represent a maximal risk for lung cancer. COPD increases the risk of 
developing lung cancer possibly due to the loss of the clearing capacity of the mucociliary sys-
tem as a result of toxic impact of tobacco smoke. The underlying mechanisms of cellular and 
molecular transformation and alteration are subjects of further research, whereas the close 
relationship of the exceeding probability of lung cancer in COPD patients is clear [4, 17–21].
Smoking cessation allows increase of lung function in patients with COPD. A 1-year follow-
up after smoking cessation shows a limited increase in lung function in COPD patients [3].
Smoking cessation allows optimal preservation of remaining ventilatory capacity in patients 
with COPD. Long-term observation of the course of lung function shows a lower year by year 
decrease after smoking cessation compared to continuous smokers who failed to stop [3, 22].
Only smoking cessation effectively leads to longer survival in COPD patients by the preven-
tion of progression towards respiratory impairment and failure. One of the main results of the 
lung health study is the evidence for longer survival in COPD patients after 14.5 years [23].
Smoking cessation allows the improvement of coughing, shortness of breath and bronchitis 
within weeks. Within only 4 weeks, a marked decrease of coughing and bronchitis symptoms 
as well as shortness of breath is observed after smoking cessation [24].
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3. Smoking cessation: motivation, methods and techniques
Smoking cessation as the main measure for treating COPD patients who still smoke is very well 
established in guidelines on an international and national basis an in Cochrane Reviews [25, 26].
3.1. Motivational interviewing strategy
Motivational interviewing (MI) technique [27] is a fundamental tool for initial motivation.
Primary motivation towards tobacco cessation is essential to start patient’s action. Motivational 
interviewing technique has showed to be most effective and time effective at this end. The 
technique consists, in short, in interviewing the patient himself on his own attitudes towards 
his smoking while respecting his autonomy. While doing so, the patient will produce his 
main possible reasons in favour of smoking cessation like health concerns, financial issues, 
aspects of beauty/concerns of premature ageing, being a good example for the children etc. 
While explaining these reasons to the interviewer, the patient will influence his own tendency 
to move towards cessation and thus increasing the level of his own motivation for action.
3.2. The 5A-strategy and the 5R-strategy
The therapists duty is to increase the patient‘s understanding and motivation. Clinicians can 
make a difference with even a minimal (less than 3 minutes) intervention. A relation exists 
between the intensity of intervention and tobacco cessation outcome. Even when patients are not 
willing to make a quit attempt at this time, clinician-delivered brief interventions enhance moti-
vation and increase the likelihood of future quit attempts [28]. Tobacco users are being primed 
to consider quitting by a wide range of societal and environmental factors (e.g., public health 
messages, policy changes, cessation marketing messages, family members). There is an evidence 
that smokers who receive clinician advice and assistance with quitting report greater satisfac-
tion with their health care than those who do not [29, 30]. The goal of these strategies is clear: 
to change clinical culture and practice patterns to ensure that every patient who uses tobacco is 
identified. Several observations are relevant to this theme. Although many smokers are reluctant 
to seek intensive treatments, they nevertheless can receive a brief intervention every time they 
visit. The time limits on physicians as well as reimbursement restrictions, often limit providers 
to brief interventions, although more intensive interventions would produce greater success.
The 5A technique (see Table 1) includes to “ask, advise, assess, assist, arrange…” [25].
Ask: at every single encounter, the patient is asked whether he is a smoker and how much 
the consumption is.
Advise: smokers will be given the clear advice to stop smoking for health considerations.
Assess: the smoker's willingness to take action for smoking cessation is to be assessed.
Assist: in case of the smokers willingness to quit she/he shall be given assistance to do so.
Arrange: follow-up is to be arranged to support success.
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Usually the first three steps ask/advise/assess are being applied repeatedly until finally the 
smoker might feel that his willingness to start action has reached the point.
The 5R-strategy for patients unwilling to quit–“relevance, risk, rewards, roadblocks, repetition”(see 
Table 2) has shown to be helpful [25]. Using this, the 5R technique allows advancing an individ-
ual’s state of readiness in quitting smoking, and strengthening their motivation to quit smoking.
Relevance: the relevance of quitting is discussed with the patient taking into account the indi-
vidual health condition of the person.
Risk: the individual risk of the patient if continuing smoking is being made clear.
Rewards: the improvements of health conditions the patient can expect after quitting are 
discussed.
Roadblocks: barriers that hinder the smoker to take action are discussed in detail, for exam-
ple, fear of withdrawal symptoms, fear of weight gaining etc.
Repetition: the strategy is to be performed repeatedly at every encounter with a smoker.
It has to be underlined that the main principles of the motivational interviewing technique 
shall be applied in the 5R-strategy. Among them, maintaining the smoker’s autonomy may 
be the most important: pushing the patient towards any action must be avoided. Instead, all 
discussions shall be led following a pattern like “… if you as a smoker decided to quit: what 
might be the biggest advantage for you motivating you to do so …?”
3.3. Behavioural therapy
Behavioural therapy in various strategies is outlined as the main element of effective smoking 
cessation therapy [31, 32]. There is a strong dose-response relationship between the intensity of 
Ask At every single encounter, the patient is asked whether he is a smoker and how much the 
consumption is. Patients who are most repeatedly will expect the question in subsequent meetings. 
This by itself increases the ambivalence towards the individual smoking behaviour.
Advise Smokers will be given the clear advice to stop smoking for health considerations. The advice must 
be clear without possible evasions as to the “if” and “when.” If this advice is not been given by the 
physician, the patient will interpret it as active permission to continue smoking.
Assess The smoker's willingness to take action for smoking cessation is to be assessed. If there is a 
substantial willingness to quit, the patient must be given a detailed possible instruction to proceed. 
Often, the first hint may be the patient asking for more information on how to proceed. Detailed 
information then shall be given in a neutral way respecting the patient‘s autonomy regarding his 
decision for the next step.
Assist In case of the smokers willingness to quit she/he shall be given assistance to do so. It is crucial that 
any major delay for the realisation is avoided as with time the motivational state of the patient is at 
risk.
Arrange Follow-up is to be arranged to support success. The main goal is to avoid the risk of relapse and if 
relapse happens to help the patient to resume abstinence and stabilise it. Follow-up intervals must 
be adapted individually.
Table 1. Assessment of motivation and steps towards smoking cessation: The 5A-strategy [21].
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tobacco dependence counselling and its effectiveness [33]. Interventions are designed to meet the 
smoker’s limited willingness to take part in specific interventions on one hand and the knowl-
edge that “the more the better” intervention should be intense with frequent days and long 
follow-up on the other hand. Successful interventions for smoking cessation group therapy are 
mostly restricted to 3–6 dates within 2–6 weeks with a total duration of about 10 hours. Programs 
following similar conception achieve abstinence rates of 30–45% after 12 months [34–37]. 
Behavioural therapy for smoking cessation includes psychoeducation aiming to establish a clear 
understanding of the necessity of quitting to stop negative effects mainly on health. Participants 
are being enabled to identify their personal smoking trigger situations and to develop alternative 
strategies to avoid smoking. This is done by explicitly increasing the ambivalence of the addicted 
smoker as to short-term smoking associated advantages in contrast to long-term disadvantages 
and risks. Participants receive support for preparation of their smoke stop day with detailed 
planning of the individual realisation. Participants receive detailed preparation for management 
of relapse risk situations and are being enabled for alternative strategies to avoid relapse. While 
there is a correlation of abstinence rates and intensity/duration of behavioural intervention, 
patients frequently are reluctant to accept longer behavioural interventions with multiple dates 
due to limitations from their daily life [38].
3.4. Pharmacotherapy
Pharmacotherapy can support smoking cessation therapy in patients with higher degrees of 
nicotine addiction and thus increase abstinence rates [39]. To measure total nicotine withdrawal 
Relevance The relevance of quitting is discussed with the patient taking into account the individual 
health condition of the person. This means that the patient must be enabled to develop a clear 
understanding of his personal risks concerning his disease status which she/he shall understand 
clearly. Instruction must follow the intellectual capabilities of the patient.
Risk The individual risk of the patient if continuing smoking is being made clear. Particularly for 
COPD patient, the course of her/his lung function loss with and without smoking respectively 
shall be made understood so the patient can understand how much her/his prognosis depends 
on successful quitting.
Rewards The improvements of health conditions and life conditions the patient can expect after quitting 
are discussed. This includes short-term advantages like better exercise capabilities and less 
bronchitis symptoms within weeks as well as long-term rewards like longevity and overall 
performance improvement in later years. It also includes non-health advantages like saved 
money, better cosmetic appearance, being a better example for own children, gaining autonomy 
while losing dependence on nicotine etc.
Roadblocks Barriers that hinder the smoker to take action are discussed in detail, for example, fear of 
withdrawal symptoms, fear of weight gaining etc. The therapist will ask the patient to find her/
his own strategies to overcome the individual roadblocks of the particular patient by asking him 
to develop own personal solutions.
Repetition The strategy is to be performed repeatedly at every encounter with a smoker. It is essential 
to focus on the necessity of abstinence at every meeting with the patient. Failure to bring 
the patient to action in one meeting is not a failure of the strategy. The repeated focusing on 
quitting by itself increases the patient ambivalence thus facilitating the development of eventual 
motivation towards action.
Table 2. The 5R-strategy for patients unwilling to quit [25].
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discomfort or craving, various scales may be used [40]. The major underlying mechanism for 
increased abstinence rates with pharmacotherapy support consists in the continued partial sat-
uration of nicotine specific receptors (α4β2 receptors) in the ventral tegmental area of the brain 
allowing to maintain dopaminergic activity. Under this protection regarding the direct nicotine 
addiction proportion of tobacco dependence, the behavioural changes towards abstinence are 
facilitated while the exposition to toxic components of cigarette smoke is ended.
3.5. Nicotine replacement therapy
Nicotine replacement therapy [41] is longest established in support of smoking cessation 
therapy. Various OTC applications are available. Dosage should be planned following the 
smoking consumption amount at the time of the smoke stop. Roughly, smoking one cig-
arette results in the uptake of about 2 mg of nicotine for the smoker. Given, a smoker’s 
consumption is 20 cigarettes a day, the replacement at the start of the measure should be 
roughly 40 mg. The composition of replacement products may be a basic application of a 
patch and addition of gums, lozenges or parts of oral nicotine spray to reach the amount. 
Side effects of nicotine replacement therapy are mostly restricted to irritability/impairment 
of sleep and sometimes local skin irritation (patches). Due to impaired teeth conditions, 
gums may not be applied properly. There is no evidence that NRT increases the risk of heart 
attacks [42, 43]. The toxic lethal dose of nicotine will not be reached by far due to the short 
half-time of nicotine.
3.6. Varenicline
Varenicline as a partial agonist and partial antagonist of the nicotine receptor was introduced 
for tobacco cessation therapy ever since 2006 first in the USA and then stepwise worldwide. 
The substance was suspected to cause depression and suicidal thinking and irritability as a side 
effect. Eventually studies could show, but those effects appeared due to withdrawal symptoms 
and could not be attributed to varenicline. The substance has turned out to be the most effective 
and save support of smoking cessation in various studies [44–46]. Varenicline is applied as tab-
lets to be taken twice daily. Due to nausea as a possible side effect dosage is started with 0.5 mg 
twice daily to be continued with 1 mg twice daily over 3 months. Varenicline is to be started 
about 1 week before the planned quit day. Abnormal dreams and disturbed sleep are the main 
reported side effects both disappearing after the end of the application [47]. While varenicline 
was suspected to cause psychiatric side effects like irritability, depression and suicidal tenden-
cies in the past, recent studies could show those effects as withdrawal effects. Former possible 
contraindication in psychiatric/schizophrenic patients are not maintained [46].
3.7. Bupropione
Bupropione was originally developed as an antidepressant but showed effects in support-
ing smoking cessation therapy. Due to possible side effects (lowered seizure threshold) and 
lower effectivity compared to other substances (varenicline etc.), it has now a minor role rather 
restricted to patients with depression in smoking cessation but may be taken into consideration 
for patients with depression [48].
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4. Challenges to smoking cessation in COPD
4.1. Abstinence rates
Depending on the measures taken in tobacco cessation therapy, abstinence rates after 12 months 
can vary from about 3% over baseline after short advice to stop smoking up to nearly 50% fol-
lowing combined behavioural therapy and pharmacotherapy in an intensive setting [49–54].
4.2. Degree of addiction
COPD patients have higher dependence on tobacco [55, 56]. Higher dependence scores 
require not only a more intense behavioural therapy with more face-to-face contacts [38] and 
the possibility of individual psychotherapy if needed but also longer and more consequent 
application of pharmaceutical support. For example, the application duration of varenicline 
may be prolonged in patients with late relapse [57].
4.3. Role of depression
COPD patients have a higher depression rate [56, 58–63] COPD patients with depression 
require special treatment which takes specific depressed condition and consideration. In 
patients with a non-controlled depression, treatment of the depression is ranking before 
smoking cessation. Only after successful re-compensation of the psychiatric disease, the start 
of the cessation therapy should be undertaken [64–68].
4.4. Role of reimbursement
Reimbursement of tobacco cessation measures–regardless of the fact that a smoker who quits 
will save considerable sums of money and thus might pay for the cessation intervention–
has shown to increase willingness to take part and to increase abstinence rates. It has to be 
accepted that addicted smokers have a different perception on spending considerable propor-
tions of their income on tobacco products. Also, the major proportion of addicted smokers is 
a part of the less affluent and often has difficulties to pay for smoking cessation measures/
medication at the given time when saving money with abstinence later [64, 65, 68].
4.5. Weight gain concerns
Minor weight gain after quitting average tobacco consumption is to be expected but can be 
avoided with higher physical activity [69–73]. Smoking one cigarette induces a loss of meta-
bolic energy of about 10 kcal. Thus, a person who formerly smoked 20 cigarettes per day and 
who continues usual diet as before will have an increase of available energy of about 200 kcal 
per day after quitting. This results in a weight gain of about 5–7%. The person should be 
encouraged to accept this weight gain for a limited period of time until she/he will be a well-
established secure ex-smoker with minimised relapse risk. It should be avoided to perform a 
weight control strategy while quitting as the success of the final abstinence, would be at risk 
with a double stress of smoking cessation and weight control efforts [70–72, 74].
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4.6. Professional setting
The professional frame of tobacco cessation measures like behavioural therapy and pharmaco-
therapy counselling has a marked influence on long-time abstinence rates. Performing tobacco 
cessation therapy in physician practices as an integrated part of continuous therapy of their 
underlying disease appears to have a positive effect on long-time abstinence. This may be attrib-
uted to the fact that in the practice or outpatient ambulance, the patient will be seen after ending 
cessation therapy and continuously be monitored for maintaining abstinence, thus expecting spe-
cific questions from the physician who treats him. This may reduce relapse probability [54, 75, 76].
5. Role of e-cigarette
The e-cigarette is being introduced progressively as a possible instrument on the way to tobacco 
cessation and/or a measure of harm reduction respectively [77–79]. Increasing evidence appears 
to show that the e-cigarette may be helpful in smoking cessation particularly if containing a 
sufficient amount of nicotine which by itself does no harm to the respiratory system [78, 80].
Cell culture and experimental animal data indicate that e-cigs have the potential for induc-
ing inflammation, albeit much less than smoking [81]. Evidence on possible hazards from 
e-cigarettes show increasingly clear that compared to tobacco cigarettes the risk of consump-
tion of e-cigarettes is much less [82], while further research on the subject is on-going and 
necessary [83]. Recent research could show exposure to toxic and carcinogenic substances 
significantly lower in users of e-cigarettes as compared to cigarette smokers [77]. The FDA 
now has regulatory authority over e-cigs and can regulate product and e-liquid design fea-
tures, such as nicotine content and delivery, voltage, e-liquid formulations and flavours. For 
patients who show no realistic willingness or ability of quitting and who in particular are not 
willing to apply nicotine replacement therapy products, the alternative of using E-cigarettes 
can be taken into consideration. Mainly two major potential risks of e-cigarette are being dis-
cussed at present. E-cigarettes might lead the consumer—mostly adolescents—into a tobacco 
cigarette consumer career, thus inducing possible lifelong addiction. E-cigarettes might con-
tain compounds that might cause lung cancer although at a lower risk than tobacco cigarettes 
do. Both concerns hardly apply for COPD patients in far progressed stages of the disease 
where respiratory function by itself is acutely at risk. In particular for these COPD patients 
with highest degree of loss of lung function, the main goal must be to urgently avoid any fur-
ther contact of toxic tobacco smoke with the bronchi. However, a great proportion of COPD 
patients in this situation due to their mental capacities and their addiction are not willing or 
able to avoid cigarette smoke by simply applying nicotine replacement as they will not be 
able to change their smoking habits which they feel can be preserved by using the e-cigarette. 
Thus, the goal of avoiding toxic smoke may be achieved by the application of e-cigarette 
vapour instead of tobacco smoke with high content of toxic and carcinogenic components. 
With more legal regulations on e-cigarette products worldwide and with a growing body of 
evidence on the toxic and carcinogenic potential, the role in smoking cessation/harm reduc-
tion will become clearer.
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6. Summary
Smoking is the major cause of COPD resulting in respiratory impairment and increased mor-
tality. Smoking cessation is the single effective intervention to mitigate the development of 
COPD. Most smokers are addicted to cigarettes, thus lacking control of consumption and abil-
ity to quit. Standardised motivation strategies in use elevated rates of willingness for smokers 
to consider quitting. High abstinence rates can be achieved by combination of behavioural 
therapy and pharmaceutical support. Medications to support behavioural therapy are effec-
tive and safe. Reimbursement of smoking cessation measures increases willingness and absti-
nence rates, where smoking cessation is not a realistic option patient with end-stage COPD, 
may benefit from the use of e-cigarette.
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